102195-80-2

Basic information

• Product Name: BOC-4-OXO-PRO-OME
• Synonyms: BOC-PRO-(4-KETO)-OME;BOC-4-OXO-PRO-OME;BOC-4-OXO-L-PROLINE METHYL ESTER;BOC-GAMMA-KETO-L-PROLINE METHYL ESTER;BOC-L-PRO(4-O)-OME;BOC-L-PRO(4-OXO)-OME;(S)-N-ALPHA-TERT-BUTYLOXYCARBONYL-4-OXO-PROLINE METHYL ESTER;N-T-BOC-4-OXO-L-PROLINE METHYL ESTER
• CAS NO: 102195-80-2
• Molecular Formula: C₁₁H₁₇NO₅
• Molecular Weight: 243.26
• EINECS: 1308068-626-2
• Product Categories: Amino Acids;Boc-Amino Acids and Derivative;Boc-Amino acid series;Amino Acids & Derivatives;Heterocycles
• Mol File: 102195-80-2.mol

Chemical Properties

• Melting Point: 35-40°C
• Boiling Point: 333.149 °C at 760 mmHg
• Flash Point: 110 °C
• Appearance: /
• Density: 1.21 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.488
• Storage Temp.: ?20°C
• PKA: -3.86±0.40(Predicted)
• CAS DataBase Reference: BOC-4-OXO-PRO-OME(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-4-OXO-PRO-OME(102195-80-2)
• EPA Substance Registry System: BOC-4-OXO-PRO-OME(102195-80-2)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-41
• Safety Statements: 26-36/37-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 102195-80-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
BOC-4-OXO-PRO-OME is used as a synthetic building block for the creation of various organic compounds. Its chemical structure allows it to be a versatile component in the synthesis of complex molecules, making it a valuable asset in the field of organic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, BOC-4-OXO-PRO-OME is used as an intermediate in the development of new drugs. Its unique properties enable it to be a key component in the synthesis of potential therapeutic agents, contributing to the advancement of medical treatments.
Used in Chemical Research:
BOC-4-OXO-PRO-OME is also utilized in chemical research as a model compound for studying various reaction mechanisms and understanding the behavior of similar molecules. This helps researchers gain insights into the properties and reactivity of related compounds, furthering the knowledge in the field of chemistry.

InChI:InChI=1/C11H17NO5/c1-11(2,3)17-10(15)12-6-7(13)5-8(12)9(14)16-4/h8H,5-6H2,1-4H3/t8-/m0/s1

Upstream product

• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51-35-4 4R-4-hydroxyproline 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 876317-19-0 ⁽²⁸⁾-1-(tert-butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid 
• 84348-37-8 N-tert-butoxycarbonyl-4-oxo-L-proline 
• 79-37-8 oxalyl dichloride 
• 796095-60-8 (2S)-1-tert-butoxycarbonyl-2-(methoxycarbonyl)-4-hydroxyazacyclopentane 
• 67-68-5 dimethyl sulfoxide 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 7529-22-8 4-methylmorpholine N-oxide 
• 1063998-64-0 (2S,4R)-4-Hydroxy-pyrrolidine-2-carbonyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 84348-39-0 (S)-1-tert-butyl 2-methyl 4-methylenepyrrolidine-1,2-dicarboxylate 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 284047-07-0 (S)-4-[1-(4-Isopropyl-phenyl)-meth-(E)-ylidene]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 470482-36-1 (2S)-1-tert-butyl 2-methyl 4-hydroxy-4-(trifluoromethyl)pyrrolidine-1,2-dicarboxylate 
• 934470-91-4 1-tert-butyl 2-methyl (2S)-4-(2,6-dimethylphenyl)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate 
• 934471-03-1 1-tert-butyl 2-methyl (2S,4R)-4-(2,6-dimethylphenyl)-1,2-pyrrolidinedicarboxylate 
• 934471-20-2 (2S,4R)-1-(tert-butoxycarbonyl)-4-(2,6-dimethylphenyl)-2-pyrrolidinecarboxylic acid 
• 886447-54-7 ethyl [4-[4,4-difluoro-1-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylcarbonyl]-1-piperazinyl]acetate 
• 203866-15-3 1-(tert-butoxycarbonyl)-4,4-difluoro-L-proline 
• 147235-94-7 (2S,4S)-4-(carboxymethyl)pyrrolidine-2-carboxylic acid 
• 835923-28-9 methyl (2S,4S)-4-[2'-(6'-methoxypyridyl)]pyrrolidine-2-carboxylate 
• 835923-35-8 N-benzyl-5(S)-[2'-(6'-methoxypyridyl)]-2-piperidone 
• 807310-56-1 (+)-N-benzylcytisine 
• 835923-38-1 (3R,5S)-N-benzyl-3-hydroxymethyl-5-[2'-(6'-methoxypyridyl)]piperidine 

Relevant articles and documents

Stereoselective synthesis of Boc-protected cis and trans-4-trifluoromethylprolines by asymmetric hydrogenation reactions

Stereocontrolled synthesis of cis and trans-substituted prolines by a divergent approach, leads to the preparation of cis-(4S)- and trans-(4R)-trifluoromethyl-Lproline from hydroxyproline. The key pyrroline intermediates were subjected to hydrogenation (s

Asymmetric synthesis of lycoperdic acid

Lycoperdic acid [(2S,5'S)-2-amino-3-(5'-carboxy-2'-oxo-5'- tetrahydrofuranyl)propanoic acid], isolated from the mushroom Lycoperdon perlatum, was synthesized from trans-4-hydroxy-L-proline by a six-step route involving samarium diiodide (SmI2)-mediated formation of the spiro-γ- lactone and ruthenium tetroxide (RuO4) oxidation of the L-proline ring system to the L-pyroglutamic acid moiety. Lycoperdic acid (1) was found to undergo hydrolysis of the γ-lactone ring in 1 N hydrochloric acid at 23°C, giving an equilibrated mixture of 1 and the corresponding hydroxy acid.

γ-(S)-Trifluoromethyl proline: Evaluation as a structural substitute of proline for solid state 19F-NMR peptide studies

γ-(4S)-Trifluoromethyl proline was synthesised according to a modified literature protocol with improved yield on a multigram scale. Conformational properties of the amide bond formed by the amino acid were characterised using N-acetyl methyl ester model. The amide populations (s-trans vs. s-cis) and thermodynamic parameters of the isomerization were found to be similar to the corresponding values for intact proline. Therefore, the γ-trifluoromethyl proline was suggested as a structurally low-disturbing proline substitution in peptides for their structural studies by 19F-NMR. Indeed, the exchange of native proline for γ-trifluoromethyl proline in the peptide antibiotic gramicidin S was shown to preserve the overall amphipathic peptide structure. The utility of the amino acid as a selective 19F-NMR label was demonstrated by observing the re-alignment of the labelled gramicidin S in oriented lipid bilayers. This journal is

Synthesis of N-t-Butoxycarbonyl-4,4-dideuterio-L-proline

The title compound, which is useful for structural investigations of proline-containing peptides by 1H-N.M.R. spectroscopy, has been synthesized in five simple steps from N-t-butoxycarbonyl-4-hydroxyproline and designed for a maximal deuterium incorporation.The deuterium content was nearly 90percent.

VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER

Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be

Pyrimidine derivative and application thereof in medicines

The invention discloses a pyrimidine derivative and application thereof in medicines, and particularly relates to a novel pyrimidine derivative and a pharmaceutical composition containing the compound. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preparation of drugs for treating KRAS G12C-mediated diseases and/or symptoms, especially in preparation of drugs for treating cancers.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.